Navigation Links
Regulus to Present at the Lazard Capital Markets Healthcare Conference
Date:11/8/2012

LA JOLLA, Calif., Nov. 8, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Lazard Capital Markets 9th Annual Healthcare Conference on Wednesday, November 14, 2012 at 1:00 PM EST at the Pierre Hotel in New York City. 

The presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of the Company's website at www.regulusrx.com.  A replay of the webcast will be archived on the Company's website for two weeks following the presentation date.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (NASDAQ: ALNY) and Isis Pharmaceuticals (NASDAQ: ISIS). Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Loo
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
2. Regulus Therapeutics Appoints Bruce Carter to its Board of Directors
3. Regulus Files Registration Statement for Proposed Initial Public Offering
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
6. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
9. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
10. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
11. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... most natural and synthetic processes prefer to settle ... or energyit is within the realm of non-equilibrium ... constant changes in energy and phases, such as ... conditions allow humans to regulate their body temperature, ... with seismic activity. , But even though ...
(Date:7/24/2014)... July 24, 2014 Your cell ... in modeling lithium-ion battery storage capacity. , New ... a theoretical model created at Lawrence Livermore ... that predicts how carbon components will perform as ... emphasizes the urgent need for higher-performance batteries. Several ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
(Date:7/24/2014)... N.J. , July 24, 2014 ... provider of regulatory and ethical review services for ... Alliance Biosciences. Formerly a division of ... was the leading biosafety and biosecurity consulting firm ... With this addition, WCG,s biosafety division – WCG ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system ... results of the GRAVITAS trial have been published in T he ... m erican M e dic a ... i o n (1). First presented at the American ...
... 15, 2011 The following is being issued by the ... Obama,s push for a greater investment in U.S. science, technology, ... of CNBC,s Sunday, March 13, broadcast of " The Wall ... interviews with The Pew Charitable Trusts President and ...
... CAMBRIDGE, Mass., March 15, 2011 Biotechnology company ... operations in Cambridge, Massachusetts and is advancing its ... and monitoring tool for celiac disease. The company ... targeted immunotherapies from Nexpep Pty., Ltd., based in ...
Cached Biology Technology:Accumetrics Announces Publication of GRAVITAS Primary Results in JAMA 2Accumetrics Announces Publication of GRAVITAS Primary Results in JAMA 3Investing in Biomedical Innovation 2Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy 2Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy 3Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy 4
(Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... on different species of fish, according to a ... Exeter which tested fish anti-predator behaviour. , ... predator model when exposed to additional noise, whereas ... , Lead author Dr Irene Voellmy of Bristol,s ... many aquatic environments have increased substantially during the ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... on interdisciplinary research is now leading to breakthroughs in ... has become a reality. Four years ago, ... research project herself when she started with her team ... Together with colleagues at the Nano-Science Center, her team ...
... a fatty fast food meal is never good for you, ... worse, according to a new University of Guelph study. ... person,s blood sugar levels spike after eating a high-fat meal, ... meal and caffeinated coffee jumping to levels similar to ...
... NEW YORK, March 31, 2011 Hoyos Group ... Chief Marketing Officer, effective April 1, 2011. ... a member of Hoyos Group,s senior executive team, ... marketing, strategic business development, brand strategy, positioning and ...
Cached Biology News:From science fiction to research breakthrough 2Got a craving for fast food? Skip the coffee, study says 2Hoyos Group Appoints Anthony Antolino as Chief Marketing Officer 2Hoyos Group Appoints Anthony Antolino as Chief Marketing Officer 3
This Dedicated 18" X 18" (45.7 X 45.7 cm.) shaker platforms are optimized for a particular flask clip size. Dedicated platforms come fully loaded with flask clips....
... VARIOKLAV 75 S and 135 S steam sterilizers ... bottoms combine the advantages of a double-walled device ... effective deaeration and drying by built-in jacket heater ... fast cooling. The chamber is free of furnishings ...
... Shakers combine high durability and performance ... The patented triple-counterbalanced heavy-duty mechanism ... run with heavy out-of-balance loads. ... contamination. The heavy stainless steel ...
... 4300 System features Saga GT , is ... automates electrophoresis, lane finding, location of standards, ... ,Saga GT is second generation software ... initially developed at the University of Washington ...
Biology Products: